Voluntary announcement - first patient dose of ct1190b in china phase i registrational trial
Filed with HKEX · Stock code 2171 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Carsgen Therapeutics
- CARsgen Therapeutics Announces 2026 Interim Results
- CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
- CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
- Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting